Sama Therapeutics is a precision neuropsychiatry AI/ML platform that synthesizes and validates predictive biomarkers grounded in neural, physiological, multi-omics, natural language, and behavioral phenotypes. The company's agile SaaS platform, iMAGiNE™, analyzes the transdiagnostic efficacy of pharmaceutical and neurostimulation modalities through precision clinical trials, causal inference, preclinical translation, and generative AI trained on proprietary and open-science datasets. With an extraordinarily interdisciplinary team, Sama Therapeutics is advancing "software as medical device" for a range of indications, including cognitive, affective, interoceptive, and substance use disorders. We invite partners to join our mission unlocking brain health through integrative neurotechnology and proven “transprognostic” algorithms: https://brainclinics.com/tdbrain-challenge/
Please reach out to contact@sama.ac for more information and a live demo.
Company Details
- Employees
- 25
- Founded
- -
- Address
- 1 Leighton St #1904, Cambridge,ma 02141,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://sama.ac/
- HQ
- Cambridge, MA
Sama Therapeutics Questions
Sama Therapeutics's website is https://sama.ac/
Sama Therapeutics's LinkedIn profile is https://www.linkedin.com/company/sama-therapeutics
Sama Therapeutics has
25 employees.
View email and phone details for 25
employees at Sama Therapeutics.
Sama Therapeutics's industry is
Biotechnology Research
Sama Therapeutics's top competitors are
Ceretype Neuromedicine, Inc.,
Vagus Labs,
Holobiome,
Guidepoint,
Neumarker Inc.,
Alto Neuroscience,
Unityai,
Modality.ai,
Thynk Inc,
Cumulus Neuroscience.
Sama Therapeutics's categories are Biotechnology Research
Sama Therapeutics's founding year is 2022
